In this eighth installment, Shubham Pant, MD, and Michael Pishvaian, MD, PhD, discuss their approach on deciding which treatment options, FOLFIRINOX or NALIRIFOX, are best suited for the patients that they treat.

In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.

In this sixth installment, Tanios Bekaii-Saab, MD, and Shubham Pant, MD, discuss the role cost plays in selecting cancer regimens.

In this fifth installment, Shubham Pant, MD, and Tanios Bekaii-Saab, MD, discuss the best practices for treating adverse events associated with treatments such as FOLFIRINOX or NALIRIFOX.

In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer.